
Wednesday, April 03, 2024 1:17:22 PM

Recent HYMC News
- Hycroft Announces Exercise and Closing of Underwriters' Option • PR Newswire (US) • 07/14/2025 01:00:00 PM
- HYCROFT ANNOUNCES PRICING AND UPSIZING OF PUBLIC OFFERING OF UNITS • PR Newswire (US) • 06/12/2025 01:11:00 PM
- HYCROFT ANNOUNCES PRICING AND UPSIZING OF PUBLIC OFFERING OF UNITS • PR Newswire (US) • 06/12/2025 01:04:00 PM
- Hycroft Announces Public Offering of Units • PR Newswire (US) • 06/11/2025 08:29:00 PM
- Hycroft Announces Public Offering of Units • PR Newswire (US) • 06/11/2025 08:23:00 PM
- Hycroft Files First Quarter 2025 10-Q and Provides Corporate Update • PR Newswire (US) • 05/14/2025 01:00:00 PM
- 2024 Year-End Exploration Results • PR Newswire (US) • 04/30/2025 01:00:00 PM
- Hycroft Files 2024 10-K and Provides Corporate Update • PR Newswire (US) • 03/05/2025 11:05:00 AM
- Hycroft Once Again Drills Best Hole Ever • PR Newswire (US) • 01/14/2025 01:00:00 PM
- HYCROFT ANNOUNCES BOARD CHAIR TRANSITION • PR Newswire (US) • 01/07/2025 01:00:00 PM
- Hycroft Announces Third Quarter 2024 Results • PR Newswire (US) • 11/05/2024 01:00:00 PM
- Hycroft Continues to Intersect High-Grade Silver at Brimstone • PR Newswire (US) • 10/24/2024 12:30:00 PM
- Hycroft Expands Vortex - Encounters Significant Silver and Gold • PR Newswire (US) • 10/03/2024 12:00:00 PM
- Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 08/23/2024 08:10:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 05:30:20 PM
- Hycroft Announces Second Quarter 2024 Results • PR Newswire (US) • 08/06/2024 01:00:00 PM
Branded Legacy Inc. Announces Leadership Transition and Pending Merger with Innovative Addiction Therapeutics Company Projecting $40 Million in First-Year Revenue • BLEG • Jul 14, 2025 1:23 PM
VAYK Project 100% Revenue Growth Before Half Year Report • VAYK • Jul 14, 2025 8:58 AM
Glidelogic Corp. Announces Release of First AI-Generated Novel "The Thirteenth Proposal" • GDLG • Jul 11, 2025 12:20 PM
Fifty1 AI Labs' REVIVE Clinical Trial Redefines Long COVID Treatment, Pioneering AI-Driven Therapies and Propelling Fifty 1 Labs, Inc. Toward $50M Valuation and Global Biotech Leadership • FITY • Jul 10, 2025 8:30 AM
Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB™, its New Sublingual Pre-Workout Supplement • ASBP • Jul 9, 2025 9:15 AM
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers • IBRX • Jul 9, 2025 9:00 AM